Perspectives on Key Presentations in GI Cancer from ASCO-GI 2022: Part I

Rapid Reactions

Rapid Reactions is a video series that provides commentary from key experts summarizing data released at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) focused on gastric, gastroesophageal, and esophageal cancer. Please join Minsig Choi, MD, from Stonybrook University Cancer Center, as he discusses the following 3 pivotal presentations from ASCO-GI 2022:

  • Updated results of the CheckMate-649 study indicated that nivolumab plus chemotherapy continued to demonstrate clinically meaningful improvement in efficacy with longer follow-up, with no emergence of new safety issues
  • Results of the multicohort phase 1/2 KRYSTAL-1 study indicated that adagrasib monotherapy was well tolerated and demonstrated encouraging clinical activity in pretreated patients with GI tumors harboring a KRAS G12C mutation
  • Updated results of the DESTINY-Gastric01 trial indicated that T-DXd therapy continued to demonstrate overall survival benefit compared with chemotherapy, accompanied by a manageable safety profile, in previously treated patients with HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma

Read the Articles Discussed in the Video

  1. Nivolumab plus Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: Expanded Analysis from CheckMate 649
  2. KRYSTAL-1: Adagrasib in Previously Treated Patients with Unresectable or Metastatic Pancreatic Cancer and Other Gastrointestinal Tumors with a KRAS G12C Mutation
  3. Improved Survival with Trastuzumab Deruxtecan in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DESTINY-Gastric01

Uncategorized - August 7, 2015

Asthma and the Role of Managed Care Pharmacy

Managed care organizations (MCOs) allocate resources to improve the quality of asthma care while controlling asthma-related drug costs. MCOs that are accredited by the National Committee for Quality Assurance (NCQA) focus on Healthcare Effectiveness Data and Information Set (HEDIS) measures to develop management strategies for drugs. NCQA-accredited MCOs strive to [ Read More ]

Uncategorized - September 17, 2018

Best Practices in Biomarker-Assisted Targeted Therapy in Lung Cancer: Lessons Learned From the Yale Cancer Center

Introduction The last decade has witnessed significant advances in the development of biomarkers in oncology that play a critical role in the understanding of molecular and cellular mechanisms that drive tumor initiation, maintenance, and progression. Clinical molecular diagnostics and biomarker discoveries in oncology are advancing rapidly as investigators begin to [ Read More ]